Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of SIBA (D) or SIBA (E) versus insulin glargine with NovoRapid in type 1 diabetes
2007-002474-60Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of insulin degludec, insulin glargine and insulin aspart in diabetes mellitus type 1 (T1D) (3 arms), sponsored by Novo Nordisk. Primary endpoint: HbA1c after 16 weeks of treatment. Started Aug 2007; status: completed.
02
Drugs
insulin degludecinsulin glargineinsulin aspart
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2007-002474-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002474-60.